{"id":18455,"date":"2026-11-12T08:30:00","date_gmt":"2026-11-12T07:30:00","guid":{"rendered":"https:\/\/www.maunakeatech.com\/?p=18455"},"modified":"2026-11-12T15:16:54","modified_gmt":"2026-11-12T14:16:54","slug":"pancreatic-cancer-awareness-month-understanding-cellvizio-in-clinical-practice","status":"publish","type":"post","link":"https:\/\/www.maunakeatech.com\/int\/news-int\/pancreatic-cancer-awareness-month-understanding-cellvizio-in-clinical-practice\/","title":{"rendered":"PANCREATIC CANCER AWARENESS MONTH: UNDERSTANDING CELLVIZIO\u00ae IN CLINICAL PRACTICE\u00a0"},"content":{"rendered":"\n

Dear Shareholders and Investors, <\/strong><\/p>\n\n\n\n

November is Pancreatic Cancer Awareness Month. It highlights a major public health challenge that concerns us all: with the widespread use of cross-sectional imaging (CT and MRI), pancreatic cyst lesions are now detected by chance in 3% to 10% of adults<\/strong>. For both physicians and patients, the critical challenge is to reliably distinguish benign cysts\u2014to avoid unnecessary major surgery\u2014from cysts that may progress to pancreatic cancer. <\/p>\n\n\n\n

In this key indication, Mauna Kea Technologies<\/strong> provides a concrete answer with Cellvizio\u00ae<\/sup><\/strong>. By enabling physicians to observe the inner wall of the cyst in real time at the cellular level during an endoscopic procedure, our technology is increasingly establishing itself as a clinical standard of care<\/strong>, backed by landmark multicenter clinical studies, medical society guidelines, and an established reimbursement framework in the United States, our largest market. <\/p>\n\n\n\n

To help you better understand what we do and visualize how this clinical application works in practice, we are pleased to share a new dedicated interactive page in our Investor Relations section: <\/p>\n\n\n\n

Explore our interactive page (English Version) <\/a><\/strong><\/p>\n\n\n\n

To go further on this indication: <\/strong><\/p>\n\n\n\n